|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.09.25 - 23:42
|
XFRA: DIVIDEND/INTEREST INFORMATION - 26.09.2025 - US4448591028 (XETRA)
|
|
|
Das Instrument HUM US4448591028 HUMANA INC. DL-,166 EQUITY wird cum Dividende/Zinsen gehandelt am 25.09.2025 und ex Dividende/Zinsen am 26.09.2025
The instrument HUM US4448591028 HUMANA INC. DL-,166 EQUITY has its pre-dividend/interest day on 25.09.2025 and its ex-dividend/interest day on 26.09.2025...
|
|
|
|
|
24.09.25 - 15:03
|
AttackIQ Appoints Jeffrey Rogers as Vice President of Customer Success (Business Wire)
|
|
|
Cybersecurity veteran to drive customer-centric strategy and strengthen global adoption of adversarial exposure validationSANTA CLARA, Calif.--(BUSINESS WIRE)--AttackIQ®, the leading vendor of Adversarial Exposure Validation (AEV) solutions and founding research partner of the MITRE Center for Threat-Informed Defense (CTID), today announced it has appointed Jeffrey Rogers as Vice President of Customer Success. In this role, Rogers will lead the company's customer success strategy, guiding organizations worldwide in building stronger, more resilient cybersecurity programs through adversarial exposure validation.
Rogers brings more than 20 years of cybersecurity leadership experience, with a career dedicated to helping organizations maximize the value of their security investments. He most recently served as Vice President of Global Client Success and Support at Cyware. Previously, he held senior roles at Authentic8, Cofense (formerly PhishMe), and Humana, where he began his career in internal audit and s...
|
|
|
22.09.25 - 17:09
|
Humana Aktie: Mehr Chancen als Risiken? (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Humana-Aktienanalyse von Evercore ISI:
Evercore ISI habe die Coverage der Aktie von Humana Inc. (ISIN: US4448591028, WKN: 856584, Ticker-Symbol: HUM, NYSE-Symbol: HUM) mit einem "in line" -Rating und einem Kursziel von 295 US-Dollar aufgenommen. Das Analysehaus habe kurzfristige Bedenken hinsichtlich einer möglichen Fehlbepreisung bei Medicare Advantage im Jahr 2026 geäußert. [mehr]...
|
|
|
|
|
|
|
|
|
15.09.25 - 22:48
|
Post Acute Analytics Closes New Round of Financing to Drive Innovation in Post-Acute Care (Business Wire)
|
|
|
DALLAS--(BUSINESS WIRE)--Post Acute Analytics (“PAA”), the industry leader in intelligent care transition solutions, today announced the successful close of its latest funding round. The financing included participation from Humana and one other strategic investor, as well as existing investors, including Warburg Pincus, Dorilton Capital, and Generator Ventures.
This latest raise marks a major milestone in PAA's mission to transform how patients transition across care settings. The capital will be used to accelerate growth of Anna™, PAA's clinically intelligent proprietary platform, and to deepen the company's partnerships across providers and payers, ultimately improving patient experience and lowering avoidable cost of care. This was a strong outcome for PAA shareholders and customers, ultimately allowing PAA to accelerate bringing to market solutions that benefit members with safer transitions, improved experience, and greater transparency of care.
“This raise is a strong validation of our s...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
